121 related articles for article (PubMed ID: 32956018)
1. The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.
Smit MJ; Schlecht-Louf G; Neves M; van den Bor J; Penela P; Siderius M; Bachelerie F; Mayor F
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():541-563. PubMed ID: 32956018
[TBL] [Abstract][Full Text] [Related]
2. Atypical Chemokine Receptor 3 "Senses" CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT; Chen Q; Tesmer JJG; Handel TM
Mol Pharmacol; 2023 Oct; 104(4):174-186. PubMed ID: 37474305
[TBL] [Abstract][Full Text] [Related]
3. The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker.
Yan Y; Su J; Zhang Z
Cell Mol Neurobiol; 2022 Oct; 42(7):2147-2156. PubMed ID: 34117967
[TBL] [Abstract][Full Text] [Related]
4. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
5. Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?
Motlak M; Mathews M; Al-Odat OS; Pandey MK
Cytokine; 2024 Jul; 179():156629. PubMed ID: 38704961
[TBL] [Abstract][Full Text] [Related]
6. Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes.
Schafer CT; Pauszek Iii RF; Gustavsson M; Handel TM; Millar DP
bioRxiv; 2023 Nov; ():. PubMed ID: 37961571
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3.
Zarca AM; Adlere I; Viciano CP; Arimont-Segura M; Meyrath M; Simon IA; Bebelman JP; Laan D; Custers HGJ; Janssen E; Versteegh KL; Buzink MCML; Nesheva DN; Bosma R; de Esch IJP; Vischer HF; Wijtmans M; Szpakowska M; Chevigné A; Hoffmann C; de Graaf C; Zarzycka BA; Windhorst AD; Smit MJ; Leurs R
Mol Pharmacol; 2024 Mar; 105(4):301-312. PubMed ID: 38346795
[TBL] [Abstract][Full Text] [Related]
8. Multiplex Detection of Fluorescent Chemokine Binding to CXC Chemokine Receptors by NanoBRET.
Adamska JM; Leftheriotis S; Bosma R; Vischer HF; Leurs R
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732237
[TBL] [Abstract][Full Text] [Related]
9. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth.
Govindarajan B; Sbrissa D; Pressprich M; Kim S; Rishi AK; Vaishampayan U; Cher ML; Chinni SR
Sci Rep; 2023 Nov; 13(1):20634. PubMed ID: 37996444
[TBL] [Abstract][Full Text] [Related]
10. An emerging paradigm of CXCL12 involvement in the metastatic cascade.
Anastasiadou DP; Quesnel A; Duran CL; Filippou PS; Karagiannis GS
Cytokine Growth Factor Rev; 2024 Feb; 75():12-30. PubMed ID: 37949685
[TBL] [Abstract][Full Text] [Related]
11. Bilayer lipids modulate ligand binding to atypical chemokine receptor 3.
Eberle SA; Gustavsson M
Structure; 2024 May; ():. PubMed ID: 38776922
[TBL] [Abstract][Full Text] [Related]
12. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control.
Steele MM; Jaiswal A; Delclaux I; Dryg ID; Murugan D; Femel J; Son S; du Bois H; Hill C; Leachman SA; Chang YH; Coussens LM; Anandasabapathy N; Lund AW
Nat Immunol; 2023 Apr; 24(4):664-675. PubMed ID: 36849745
[TBL] [Abstract][Full Text] [Related]
13. ACKR3 in olfactory glia cells shapes the immune defense of the olfactory mucosa.
Dietz A; Senf K; Neuhaus EM
Glia; 2024 Jun; 72(6):1183-1200. PubMed ID: 38477581
[TBL] [Abstract][Full Text] [Related]
14. DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence.
Elmansi AM; Eisa NH; Periyasamy-Thandavan S; Kondrikova G; Kondrikov D; Calkins MM; Aguilar-Pérez A; Chen J; Johnson M; Shi XM; Reitman C; McGee-Lawrence ME; Crawford KS; Dwinell MB; Volkman BF; Blumer JB; Luttrell LM; McCorvy JD; Hill WD
ACS Pharmacol Transl Sci; 2023 Jan; 6(1):22-39. PubMed ID: 36659961
[TBL] [Abstract][Full Text] [Related]
15. The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication.
Fumagalli A; Heuninck J; Pizzoccaro A; Moutin E; Koenen J; Séveno M; Durroux T; Junier MP; Schlecht-Louf G; Bachelerie F; Schütz D; Stumm R; Smit MJ; Guérineau NC; Chaumont-Dubel S; Marin P
Nat Commun; 2020 Sep; 11(1):4855. PubMed ID: 32978390
[TBL] [Abstract][Full Text] [Related]
16. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration.
Bianchi ME; Mezzapelle R
Front Immunol; 2020; 11():2109. PubMed ID: 32983169
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CXCR4-Mediated Gi1 Activation by EGF Receptor and GRK2.
Neves M; Perpiñá-Viciano C; Penela P; Hoffmann C; Mayor F
ACS Pharmacol Transl Sci; 2020 Aug; 3(4):627-634. PubMed ID: 33073183
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.
Richard-Bildstein S; Aissaoui H; Pothier J; Schäfer G; Gnerre C; Lindenberg E; Lehembre F; Pouzol L; Guerry P
J Med Chem; 2020 Dec; 63(24):15864-15882. PubMed ID: 33314938
[TBL] [Abstract][Full Text] [Related]
19. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases.
Britton C; Poznansky MC; Reeves P
FASEB J; 2021 Apr; 35(4):e21260. PubMed ID: 33715207
[TBL] [Abstract][Full Text] [Related]
20. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.
Shi Y; Riese DJ; Shen J
Front Pharmacol; 2020; 11():574667. PubMed ID: 33363463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
